Drug Trial Radar · NCT07863167
An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
660
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
Dec 30, 2028
Study completion Dec 30, 2030
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined with other anti-tumor therapies for perioperative treatment of resectable non-small cell lung cancer in adults.
Conditions
- Non-small Cell Lung Cancer
Interventions
adebrelimab + SHR-A2009Drug
adebrelimab + SHR-A2009
paclitaxel or pemetrexed combined with carboplatin +adebrelimabDrug
paclitaxel or pemetrexed combined with carboplatin +adebrelimab
adebrelimab + SHR-A2009Drug
adebrelimab + SHR-A2009 (longer-interval regimen arm)
adebrelimab + SHR-A2009Drug
adebrelimab + SHR-A2009 (shorter-interval regimen arm)
adebrelimabDrug
adebrelimab
adebeliizumab + SHR-A2009Drug
adebeliizumab + SHR-A2009 (longer-interval regimen arm)
adebeliizumab + SHR-A2009Drug
adebeliizumab + SHR-A2009 (shorter-interval regimen arm)
adebeliizumab + platinum-containing double chemotherapyDrug
adebeliizumab + platinum-containing double chemotherapy
almonertinib combined with SHR-A2009Drug
almonertinib combined with SHR-A2009 (longer-interval regimen arm)
almonertinib combined with SHR-A2009Drug
almonertinib combined with SHR-A2009 (shorter-interval regimen arm)
almonertinibDrug
almonertinib
SHR-A2009 combined with almonertinibDrug
SHR-A2009 combined with almonertinib
almonertinib monotherapyDrug
almonertinib monotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A1 : pCR rate;Time frame: about 24 months
- Part A2 : 2-year DFS rate;Time frame: about 24 months
- Part A3 : pCR rate and 18-month EFS rate;Time frame: about 18 months
- Part B1 : 2-year DFS rate.Time frame: about 24 months
- Part B2 : MPR rate.Time frame: about 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.